4 suspended. 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Suspended 4 |
| Phase 2 | 2 | Suspended 2 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapy for Advanced Liver Cancer AlloStim® immunotherapy, FOLFOX regimen, Sorafenib - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Suspended | Mirror Biologics, Inc. | 150 | 2023-08-01 | 2025-10-23 |
| Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection postoperative antimicrobial prophylaxis, No postoperative antimicrobial prophylaxis - Hepatocellular Carcinoma, Postoperative Infection | Phase 3 | Suspended | Sun Yat-sen University | 458 | 2020-09-01 | 2020-03-25 |
| A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) Aramchol free acid, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 3 | Suspended | Galmed Research and Development, Ltd. | 157 | 2019-09-23 | 2026-02-11 |
| Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC Nivolumab and TACE/TAE, TACE/TAE - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Suspended | The Clatterbridge Cancer Centre NHS Foundation Trust | 522 | 2019-05-08 | 2025-02-26 |
Carcinoma, Hepatocellular (3) · Diabetes Mellitus (1) · Fibrosis (1) · Liver Cirrhosis (1) · Liver Neoplasms (1) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1)
Digestive System Diseases (4) · Adenocarcinoma (3) · Carcinoma (3) · Digestive System Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Liver Neoplasms (2) · Body Weight (1) · Endocrine System Diseases (1) · Fatty Liver (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1)
Folfox protocol (1) · Nivolumab (1) · Sorafenib (1) · lenvatinib (1)
Galmed Research and Development, Ltd. (1) · Mirror Biologics, Inc. (1) · Sun Yat-sen University (1) · The Clatterbridge Cancer Centre NHS Foundation Trust (1)
China (1) · France (1) · Malaysia (1) · Thailand (1) · United Kingdom (1) · United States (1)
Daniel Palmer, PhD, MD (1) · Yossi Gilgun-Sherki, PhD, MBA (1)